In the phase III trial, which was stopped early, Entresto proved superior to the ACE inhibitor enalapril, reducing the risk of cardiovascular death or heart failure hospitalisation by 20 per cent ...

Swiss pharma major Novartis (NOVN: VX) is set to lay off 427 employees at its East Hanover, New Jersey, site as part of a ...

The prospect of adding HFpEF to Entresto’s label looked shaky last year however, when the drug missed its primary objective in the phase 3 PARAGON-HF trial. The 4,822-patient study missed ...

A multinational, randomized, double-blind trial comparing Entresto versus enalapril in 8,442 adult patients with symptomatic chronic heart failure (NYHA class II–IV) and systolic dysfunction ...

There are hints that the 10-year benefit seen in STICHES, the earlier trial, might be the result of inferior medical therapy.

Entresto is Novartis' biggest moneymaker ... Novartis now expects its study to wrap in 2026. "The event-driven trial was expected to readout in ~mid-25 and represents a major catalyst in the ...